RPg Family Wealth Advisory LLC lifted its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 3.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,704 shares of the exchange traded fund’s stock after buying an additional 663 shares during the quarter. RPg Family Wealth Advisory LLC’s holdings in SPDR S&P Biotech ETF were worth $1,749,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in SPDR S&P Biotech ETF by 198.6% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 9,229,000 shares of the exchange traded fund’s stock worth $911,825,000 after purchasing an additional 6,138,000 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of SPDR S&P Biotech ETF in the third quarter worth about $141,284,000. Northwestern Mutual Wealth Management Co. boosted its stake in SPDR S&P Biotech ETF by 1.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,145,049 shares of the exchange traded fund’s stock valued at $106,158,000 after buying an additional 18,202 shares during the last quarter. Mirae Asset Securities USA Inc. boosted its stake in SPDR S&P Biotech ETF by 50.0% during the third quarter. Mirae Asset Securities USA Inc. now owns 900,000 shares of the exchange traded fund’s stock valued at $88,920,000 after buying an additional 300,000 shares during the last quarter. Finally, Employees Retirement System of Texas grew its holdings in SPDR S&P Biotech ETF by 40.8% during the 2nd quarter. Employees Retirement System of Texas now owns 603,857 shares of the exchange traded fund’s stock valued at $55,984,000 after buying an additional 174,857 shares in the last quarter.
SPDR S&P Biotech ETF Price Performance
Shares of XBI opened at $98.85 on Wednesday. SPDR S&P Biotech ETF has a 1 year low of $71.99 and a 1 year high of $105.47. The business’s 50 day simple moving average is $98.37 and its 200-day simple moving average is $96.38. The stock has a market capitalization of $7.53 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- ESG Stocks, What Investors Should Know
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Compound Interest and Why It Matters When Investing
- 2 Generic Drug Stocks Ready to Surge in 2025
- What is a Stock Market Index and How Do You Use Them?
- 3 Small-Cap Stocks That Are Ready to Rocket Higher
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.